ENTIER LIMITED

Company number SC342922 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Score: B-

The company presents a solvent, liquid balance sheet and is up to date with statutory filings, but profitability has weakened materially and ownership is subject to a regulatory divestment order. This is comparable to a patient with stable vital signs but a declining metabolic rate and a pending treatment decision.


Key Vital Signs

1. Liquidity – blood pressure
Cash at year end was £4.99 million, up from £2.70 million the prior year. Net current assets (working capital) were £5.7 million, indicating the company can meet its short-term obligations comfortably. However, the accounts note that the cash increase includes a £2.0 million intercompany loan received from Aramark Limited in January 2025. Part of the improvement is therefore an external transfusion rather than purely operational cash generation.

2. Solvency – heart health
Net assets stood at £6.17 million against total assets of £17.30 million, implying total liabilities of roughly £11.13 million. Shareholders’ funds equal net assets, meaning the business is funded predominantly by equity rather than debt. The equity ratio is approximately 36%, a strong cushion against losses.

3. Profitability – metabolism
Turnover fell 15.5% from £82.6 million to £69.7 million. Gross profit fell from £9.1 million to £6.2 million, with gross margin compressing from 11.0% to 8.8%. EBITDA declined from £3.8 million to £2.8 million, and operating profit from £3.5 million to £2.4 million. These are clear symptoms of a slowing metabolic rate: the business is generating less profit from each pound of revenue.

4. Cash circulation
While the cash balance improved, the underlying operating cash position should be viewed alongside the intercompany loan and the absence of dividends in 2025 (compared with £605,354 in 2024). Retaining profits supports liquidity, but the revenue decline needs to be reversed for sustainable cash generation.

5. Regulatory compliance – vaccinations
Accounts and confirmation statement filings are not overdue. The next accounts are due by 30 June 2027 and the confirmation statement by 29 May 2027. This indicates good administrative health.

6. Ownership stability – immune system
Aramark Limited holds more than 75% of shares and voting rights and can appoint and remove directors. Other significant interests are held by BGF-related entities and two individuals, each in the 25–50% range. Following the year end, the Competition and Markets Authority made a Final Order requiring Aramark to divest its 90% shareholding. This creates material uncertainty about who will control the company going forward, although the directors state they expect the group to remain a going concern for at least twelve months.


Diagnosis

Overall condition: Guarded but stable.

The business is not in immediate distress. It holds ample cash, positive working capital, and a solvent balance sheet. It remains profitable, though margins are narrowing.

Symptoms revealed by the numbers:

  • Revenue contraction: The 15.5% turnover decline is attributed in the accounts to the UK fiscal regime and its impact on North Sea clients and projects, with several client units idled.
  • Margin erosion: Gross margin fell from 11.0% to 8.8%, suggesting cost pressures or pricing pressure in key contracts.
  • Profit compression: EBITDA and operating profit both fell by roughly one-quarter to one-third.
  • Workforce adjustment: Group headcount reduced by 15%, consistent with lower activity.

The principal risk is not insolvency but strategic uncertainty. The CMA divestment order means the controlling shareholder must sell, and the identity of the purchaser is not yet known. Until a suitable buyer is approved, the company may face distraction, potential client nervousness, and challenges in long-term planning.


Prognosis

Short term (0–12 months): Stable.
The directors have adopted the going concern basis, supported by budgets based on confirmed work. Cash reserves provide a buffer.

Medium term (1–3 years): Uncertain.
The outlook depends on (i) the divestment process and the new owner’s strategy, (ii) recovery in North Sea oil and gas activity, and (iii) success in diversifying into marine and renewables. The confirmed events pipeline of over £4.0 million for 2025/26 is modest relative to annual turnover of £69.7 million, so new business development is critical.

Long term (3+ years): Dependent on transition and repositioning.
If the company can stabilize revenue and protect margins, the strong balance sheet provides a platform for recovery.


Recommendations

  1. Manage cash conservatively: Treat the £2.0 million intercompany loan as short-term support, not permanent funding. Monitor working capital closely and avoid over-trading while revenue is down.
  2. Protect margin: Review pricing, supplier contracts, and delivery costs to arrest gross margin erosion. A return toward the prior 11.0% gross margin would significantly improve profit.
  3. Diversify revenue: Accelerate pursuit of marine and renewables opportunities and reduce reliance on North Sea oil and gas clients.
  4. Prepare for ownership transition: Maintain key customer and supplier relationships, retain critical staff, and ensure management continuity during the divestment process.
  5. Maintain compliance: Keep accounts and confirmation statements up to date; there are currently no overdue filings.
  6. Scenario planning: Model the financial impact of different ownership outcomes and potential changes in client demand, so the board can respond quickly once the CMA process concludes.

Perspective: Financial Health Diagnostician · Model: nvidia/nemotron-3.5-super-vl:free · Generated 16 November 2026